SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's stock is trending amid upgrades from analysts, though some community members express concern over valuation relative to competitors and potential interconnect hurdles in the AI sector. Despite strong earnings, the stock experienced a selloff, leading to discussions about a possible short squeeze and whether AI constitutes a bubble.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing heavy volatility, sparking discussions about a potential market correction and whether dip-buying strategies will continue to pay off. Some community members are pointing to broader macroeconomic concerns and the influence of crypto markets, while others are eyeing key support levels for potential reversals. The conversation highlights uncertainty around near-term market direction.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to strong Q3 earnings and raised FY26 guidance, sparking bullish sentiment among investors; discussions include the impact of e-commerce growth and a planned move to the Nasdaq. Community members are debating whether Walmart's performance signals broader economic strength or if it's a safe haven during market uncertainty, while also pondering its valuation relative to tech companies.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, frustrating investors who cite strong deliveries and question the stock's valuation relative to peers. Community members speculate about market manipulation and potential short squeezes while bracing for upcoming earnings. Despite the negative price action, some investors remain optimistic, viewing the current dip as a buying opportunity based on the company's long-term potential.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the price of Bitcoin fluctuates, impacting MicroStrategy's value as a major BTC holder; the community is closely watching key support levels. Discussions revolve around analyst Tom Lee's commentary and potential short squeezes, with some expressing concerns about solvency and potential liquidation. Recent whale activity and overall market sentiment add to the volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess its volatile movements amidst optimism in the AI sector. Community discussions revolve around dip-buying strategies and potential profit-taking points, especially with upcoming earnings from key semiconductor players like NVDA. The ongoing government shutdown and concerns about AI valuations add to the uncertainty surrounding this leveraged ETF.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst overall crypto market volatility and the launch of new ETFs, sparking debates on their potential impact. Community discussions revolve around whether XRP can decouple from Bitcoin's influence and the significance of upcoming ISO20022 compliance. Some traders express frustration with price stagnation, while others remain optimistic about long-term utility and institutional adoption.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buffett's Investing Lessons: What They Mean for ETF Investors

Buffett's final lessons guide ETF investors toward discipline, cash strength and quality picks like SPY, ITOT, VTV and MINT.

<ul class="summary-bullets"><li>USA Rare Earth said that the acquisition represents a significant acceleration of its magnet-to-mine strategy, establishing an end-to-end rare earth supply chain.&nbsp;</li><li>The deal would enable LCM to continue expanding and serving its global customer base with a broad portfolio of rare earth and critical metals and alloys.</li><li>The deal comes on the heels of the Trump administration’s attempt to boost U.S. production of critical minerals and the government has invested in a few rare earth companies, including MP Materials and Trilogy Metals.</li></ul>USA Rare Earth (USAR) shares rose nearly 3% in premarket trading on Wednesday after the company announced that it had received regulatory approval from the UK Minister of State for its acquisition of LCM.The company said that it has now received the only regulatory approval required and expects to close the acquisition on time, in line with its target for the fourth quarter of calendar year 2025.<h2 class="st-heading-2">Rare Earth Push In The US</h2>The deal comes on the heels of the Trump administration’s attempt to boost U.S. production of critical minerals, and the government has invested in a few rare earth companies, including MP Materials and Trilogy Metals.The U.S. and China have also reached an agreement to ease rare-earth exports for at least a year. According to a White House Memo, China will issue general licenses valid for the export of rare earths, gallium, germanium, antimony, and graphite, benefiting U.S. end-users and their suppliers worldwide.The general license means the de facto removal of controls China imposed since 2023.<h2 class="st-heading-2">USA Rare Earth, LCM Deal</h2>USA Rare Earth said that the acquisition represents a significant acceleration of its magnet-to-mine strategy, establishing an end-to-end rare earth supply chain. The deal would enable LCM to continue expanding and serving its global customer base with a broad portfolio of rare earth and critical metals and alloys.This would also help in the supply of Neodymium Iron Boron (NdFeB) metal and strip cast alloy to USAR's Stillwater, Oklahoma magnet facility once production begins.USA Rare Earth said that LCM's metals and alloys are essential to the manufacturing of advanced magnets, semiconductors, and aerospace components. LCM supplies customers across defense, automotive, electric vehicle, industrial, and technology sectors in the U.S., UK, France, Germany, Japan, and Taiwan.Retail sentiment on USA Rare Earth remained unchanged in the ‘bearish’ territory, with message volumes at ‘low’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/USAR">Shares of USA Rare Earth</a> have gained nearly 55% this year and increased by 65% over the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-sues-global-cybercrime-ring-over-massive-smishing-campaign-report/cLPIu1eRE5Y">Google Sues Global Cybercrime Ring Over Massive Smishing Campaign: Report</a>

In this photo illustration, the USA Rare Earth logo is seen displayed on a smartphone screen.

USA Rare Earth Stock Rises After Clearing Final Regulatory Hurdle In LCM Acquisition

The company has announced that it has now received the only regulatory approval required and expects to close the acquisition on schedule, in line with its stated target for the fourth quarter of calendar year 2025.

Equity

The company has announced that it has now received the only regulatory approval required and expects to close the acquisition on schedule, in line with its stated target for the fourth quarter of calendar year 2025.


<ul class="summary-bullets"><li>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation.</li><li>The company expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.</li><li>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities.</li></ul>Ondas Holdings Inc. (ONDS) became one of the top trending tickers on Stocktwits and the company’s shares rose 4% in early trading on Tuesday following the announcement that it has entered into a definitive agreement to acquire Sentry CS, an Israel-based company in Cyber-over-RF (CoRF) and Protocol-Manipulation counter-Unmanned Aerial Systems (UAS) technology."The addition of Sentrycs will strengthen our leadership in counter-UAS and solidify Ondas' position as a full-spectrum provider of autonomous defense solutions," said Eric Brock, Chairman and CEO of Ondas Holdings.&nbsp;Ondas expects the transaction to close in November 2025. The terms of the deal were not disclosed.Retail sentiment on Ondas jumped to ‘bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Sentry CS’ Technology</h2>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation."Passive RF detection and tracking are essential to modern layered defense, and Sentrycs brings a proven technology platform already deployed across sensitive airspace, critical infrastructure, and border environments,” Brock said.Brock added that by integrating Sentry CS with Ondas’ Iron Drone Raider system, the company expects to deliver a unified detect-to-defeat solution that addresses the rapidly evolving threat landscape for its defense and homeland security customers worldwide.<h2 class="st-heading-2">Ondas’ Recent Slew Of Acquisitions</h2>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities, including robotic systems with terrestrial and subsurface AI-powered intelligence technologies.Ondas had noted that 4M Defense will expand Ondas Autonomous Systems’ addressable market into the large global landmine and UXOs clearance and subsurface intelligence platforms market.The company had also announced the acquisition of a controlling interest in Insight Intelligent Sensors, an Israeli developer of AI-driven electro-optical sensing systems.<a href="https://stocktwits.com/symbol/ONDS">Shares of Ondas</a> have gained over 771% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dennys-620-million-deal-oppenheimer-says-not-expecting-competitive-bidding-process/cL28guSR36a">Denny's $620 Million Deal: Oppenheimer Says Not Expecting ‘Competitive Bidding Process’</a>

In this photo illustration, a person holds a smartphone displaying the logo of Ondas Holdings Inc. 

ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CS

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.

<ul class="summary-bullets"><li>The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.</li><li>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. &nbsp;</li></ul>Kura Oncology (KURA) said on Friday that it received a $30 million milestone payment under its collaboration agreement with Japan-based Kyowa Kirin, inked late last year.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/24/3172720/35186/en/Kura-Oncology-Receives-30-Million-Development-Milestone-Payment-in-Ziftomenib-AML-Program-with-Kyowa-Kirin.html">payment</a> was in connection with the dosing of the first patient in a late-stage registrational program of Ziftomenib evaluating the drug in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed acute myeloid leukemia with certain conditions. The companies announced the launch of the said trial on September 29.The program includes two late-stage trials intended to support potential U.S. accelerated approval and full approval. The trial is expected to enroll patients at up to 200 sites worldwide.According to Kura, the late-stage program is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.<h2 class="st-heading-2">Terms Of The Deal</h2>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. Under the agreement, Kura is eligible to receive up to $1.2 billion in total milestone payments, including near-term milestone payments. &nbsp;As per the terms of the agreement, Kura will lead development, regulatory, and commercial strategy in the U.S. while Kyowa leads it outside the U.S.<a href="https://stocktwits.com/symbol/KURA">KURA shares</a> traded 6% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around KURA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.KURA stock is up by over 4% this year but down by about 49% over the past 12 months.Read also:<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jp-morgan-to-let-clients-use-bitcoin-ethereum-as-loan-collateral-by-year-end/cLGJVtKR3sH"> JPMorgan To Let Clients Use Bitcoin, Ethereum As Loan Collateral By Year-End: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement

The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.

<ul class="summary-bullets"><li>Viking on Thursday reported a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share.&nbsp;</li><li>Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.</li><li>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule.</li></ul>Viking Therapeutics (VKTX) received a price target hike from Morgan Stanley on Thursday on the heels of positive third-quarter updates.&nbsp;Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. The new price target represents a potential upside of 225% from the stock’s closing price on Wednesday.<h2 class="st-heading-2">Morgan Stanley’s Take</h2>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule, and the management plans to meet with the U.S. Food and Drug Administration for oral VK2735 in Q4 with a late-stage study start targeted soon after. The firm is "encouraged by swift execution across programs," the analyst added.Viking CEO Brian Lian said on Thursday that the company is expected to complete enrollment in the VANQUISH-1 study later this quarter, with VANQUISH-2 to follow in the first quarter of 2026. The VANQUISH late-stage program, including trials of Viking's subcutaneous formulation of VK2735 in patients with obesity and obesity with type 2 diabetes, was initiated in the second quarter.Viking on Thursday <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302591893.html">reported</a> a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share, according to data from Fiscal AI. The company pinned the rise in net loss for the three months ended Sept. 30, 2025, to the increase in research and development expenses.The company ended the quarter with a cash position of $715 million, which it believes provides sufficient resources to develop VK2735 through the VANQUISH clinical trials and to continue development of additional clinical programs in its pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/VKTX">VKTX shares</a> soared 7% at the time of writing. On Stocktwits, retail sentiment around VKTX jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Retail chatter around the stock rose 197% over the past 24 hours, as of Thursday morning, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:620/63;" src="data:image/png;base64,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" width="620" height="63" alt="VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>VKTX stock is down by 16% this year and by 44% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside

Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.

Buy, Hold and Build Wealth: ETFs for Long-Term Investors

Market volatility is rising but buy-and-hold ETFs like SPY, VOO and VTI offer investors diversification and long-term resilience.

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.Shares of the company soared 9% in Thursday’s pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160275/29248/en/Anavex-Life-Sciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-ANAVEX-3-71-for-the-Treatment-of-Schizophrenia.html">said</a> that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study.The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide. According to Anavex, the illness impacts 2.8 million people in the U.S. alone.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.Anavex also said on Thursday that encouraging trends were observed in biomarkers of Schizophrenia in the study that support continued development. This includes a reduced glial fibrillary acidic protein in patients receiving ANAVEX3-71 compared to placebo.GFAP is a marker of neuroinflammation, and a reduction in it suggests a potential disease-modifying effect that may become more pronounced with longer treatment durations, the company said.The company on Thursday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160281/29248/en/Anavex-Life-Sciences-Announces-Successful-Development-of-Once-Daily-Oral-Tablet-Formulation-for-the-ANAVEX-3-71-Program.html">announced</a> the successful development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing, it added.AVXL stock is down 16% this year but up approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-slashes-full-year-delivery-guidance-after-drop-in-q3-figures/chCrfpbR3OH">Rivian Slashes Full-Year Delivery Guidance After Drop In Q3 Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

The company said that its investigational drug for Schizophrenia achieved its primary endpoint in a mid-stage trial.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Shares of the company rose a whopping 161% in the pre-market session at the time of writing.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">stated</a> that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease. The company also identified a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.uniQure on Wednesday said that the therapy was generally well-tolerated in the trial with a manageable safety profile. No new drug-related serious adverse events have been observed from December 2022 to the end of June 2025, it added.Chief Medical Officer Walid Abi-Saab said that the company is looking forward to discussing the data with the U.S. Food and Drug Administration at a meeting later this year. The company plans to submit an application for approval of AMT-130 to the FDA in the first quarter of 2026 and anticipates launching it in the U.S. later in the same year.According to the company, there are currently no approved therapies to slow the progression of Huntington’s disease. The disease affects approximately 75,000 people in the U.S., EU, and the U.K., it added.QURE stock is down by 23% this year but has risen approximately 166% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

ETFs to Gain as Inflation Edges Higher in August

Inflation rose in August, but jobless claims rose, too, shaping Fed rate cut odds and boosting the appeal of large-cap blend ETFs like ITOT, EDOW and IVV. 

ITOT
iShares Core S&P Total U.S. Stock Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ITOT News

ITOTiShares Core S&P Total U.S. Stock Market ETF